Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657267 · ClinicalTrials.gov registry record · Phase 2
Dose-Intense Temozolomide in Recurrent Glioblastoma
A Phase 2 study, sponsored by Patrick Y. Wen, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00657267 is a Phase 2 study that has completed, run by Patrick Y. Wen, MD. The registered enrollment target is 58 participants.
The verdict
NCT00657267, a Phase 2 study, has completed, sponsored by Patrick Y. Wen, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas. We will be using a different dose and schedule than the FDA approved dose and schedule. The purpose of this study is to determine if patients that have failed standard temozolomide treatment will respond to temozolomide when given at a different dose and schedule (21 days every 28 days).
Interventions
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657267
The ClinicalTrials.gov registry entry for NCT00657267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Y. Wen, MD, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temozolomide is the first listed.
NCT00657267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657267 about?
NCT00657267 is a clinical study titled "Dose-Intense Temozolomide in Recurrent Glioblastoma". Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas. We will be using a different dose and schedule than the FDA approved dose and schedule. The purpose of this study is...
What is the current status of trial NCT00657267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2008-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00657267?
The interventions under investigation include: Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00657267?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.